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Drug toxicity predictionSystems approaches to studying drug-side-effect (drug-SE) associations are emerging as an active
research area for drug target discovery, drug repositioning, and drug toxicity prediction. However, cur-
rently available drug-SE association databases are far from being complete. Herein, in an effort to increase
the data completeness of current drug-SE relationship resources, we present an automatic learning
approach to accurately extract drug-SE pairs from the vast amount of published biomedical literature,
a rich knowledge source of side effect information for commercial, experimental, and even failed drugs.
For the text corpus, we used 119,085,682 MEDLINE sentences and their parse trees. We used known drug-
SE associations derived from US Food and Drug Administration (FDA) drug labels as prior knowledge to ﬁnd
relevant sentences and parse trees. We extracted syntactic patterns associated with drug-SE pairs from the
resulting set of parse trees. We developed pattern-ranking algorithms to prioritize drug-SE-speciﬁc
patterns. We then selected a set of patterns with both high precisions and recalls in order to extract
drug-SE pairs from the entire MEDLINE. In total, we extracted 38,871 drug-SE pairs from MEDLINE using
the learned patterns, the majority of which have not been captured in FDA drug labels to date. On
average, our knowledge-driven pattern-learning approach in extracting drug-SE pairs from MEDLINE
has achieved a precision of 0.833, a recall of 0.407, and an F1 of 0.545. We compared our approach to
a support vector machine (SVM)-based machine learning and a co-occurrence statistics-based approach.
We show that the pattern-learning approach is largely complementary to the SVM- and co-occurrence-
based approaches with signiﬁcantly higher precision and F1 but lower recall. We demonstrated by
correlation analysis that the extracted drug side effects correlate positively with both drug targets,
metabolism, and indications.
 2014 Elsevier Inc. All rights reserved.1. Introduction
It has been increasingly recognized that similar side effects of
seemingly unrelated drugs can be caused by their common off-
targets and that drugs with similar side effects are likely to share
molecular targets [4]. Therefore, systems approaches to studying
the phenotypic relationships among drugs and integrating this
drug phenotypic data with drug-related genetic, genomic, proteo-
mic, and chemical data can facilitate rapid drug target discovery
and drug repositioning.
Computational approaches to predicting drug targets have often
been based on chemical similarity measures and docking strategies
[14,37,27,36]. Similarly, many computational strategies for drug
repositioning have been explored [13]. The majority of theseapproaches leverage on known drug properties such as chemical
similarity [14], molecular activity similarity [19], molecular dock-
ing [16], and gene expression proﬁle similarity [12,23]. In a semi-
nal paper, Campillos et al. [4] used phenotypic side-effect
similarities among drugs to infer whether two drugs shared a tar-
get. The researchers showed that similar side effects of seemingly
unrelated drugs can be caused by their common off-targets and
that drugs with similar side effects are likely to share molecular
targets. By systematically exploiting this correlation, the research-
ers were able to predict new targets for drugs and led to a patented
reposition of a FDA-approved drug, Aprepitant. However, their
analysis was limited to drug-SE relationships derived solely from
the FDA drug labels for FDA-approved drugs. Later in this study,
we will show that much of drug-SE association knowledge from
biomedical literature have not been captured in FDA drug labels
yet. For example, only 23.8% (30 out of 126) of reported side effects
for drug irinotecan from MEDLINE are in FDA drug labels.
1 http://mbr.nlm.nih.gov/Download/index.shtml.
2 http://lucene.apache.org.
3 http://bioportal.bioontology.org/ontologies/1009.
4 http://www.meddramsso.com.
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among drugs can also lead to early prediction of unknown drug
toxicity. Existing computational approaches to predicting drug tox-
icities are mainly based on known drug targets [8,26] or chemical
structures [21,20]. The unifying assumption is that drugs with sim-
ilar in vitro protein-binding proﬁles or chemical structures tend to
exhibit similar side effects. Cami et al. have recently developed a
novel phenotype-driven approach for predicting drug toxicities
by integrating the network structure formed by known drug-SE
relationships with information on speciﬁc drugs and side effects
to predict likely unknown drug side effects [3]. Atias and Sharan
reported a novel approach to predict drug side effects by taking
into account of other drugs and their side effects [2]. Similar to
Campillos’s study, these two studies used drug-SE associations
solely derived from FDA drug labels.
The availability of a comprehensive, accurate, and machine-
understandable drug-side effect (SE) relationship knowledge base
is critical for computation-based drug target and drug toxicity pre-
dictions. Current drug phenotype-driven systems approaches rely
exclusively on drug-SE associations extracted from FDA drug
labels. However, there exists a large amount of drug-SE relation-
ship knowledge in other data sources such as FDA spontaneous
post-marketing drug safety reporting systems (FAERS), patient
electronic health records (EHRs), and the large body of published
biomedical literature. While the FDA drug labels, FAERS, and EHRs
mainly contain side effect information for FDA-approved drugs, the
vast amount of published biomedical literature contains side effect
information for drugs at all clinical stages, including investiga-
tional, approved, and failed drugs.
Currently, more than 22 million biomedical abstracts (or
records) are available on MEDLINE, making it a rich information
source of drug-SE associations. While many biomedical relation-
ship extraction tasks have focused on extracting relationships
between drugs, proteins, or genes [1,28,5,29], extracting drug-SE
relationships from MEDLINE has been less explored. The key issue
in extracting drug-SE pairs from MEDLINE is to differentiate drug-
SE (‘CAUSE’) relationship from drug-disease (‘TREAT’) treatment
relationship and from pure co-occurrences. Recently, Shetty et al.
prototyped a process for applying information mining to discover
major drug-SE associations from MEDLINE by developing a statis-
tical document classiﬁer to remove irrelevant articles [22]. Gurul-
ingappa et al. trained and tested a supervised machine learning
classiﬁer to classify drug-condition pairs in a set of 2972 manually
annotated case reports [10]. Both studies focused on a limited set
of drugs, side effects or speciﬁc article types. It is unclear how
these approaches can be scaled up to the whole MEDLINE in effec-
tively building a comprehensive drug-SE relationship knowledge
base. Recently, we developed an approach in boosting drug safety
signal detection from FAERS using evidence from MEDLINE [31].
We also developed an automatic approach to extract anticancer
drug-speciﬁc side effects from MEDLINE by developing speciﬁc ﬁl-
tering and ranking schemes [30]. However, those ﬁltering and
ranking methods were speciﬁcally targeted to extract anticancer
drug-SE relationships and cannot be generalized for other types
of drug-SE relationship extraction tasks. In one of our recent stud-
ies in building a disease phenotype knowledge base, we developed
a pattern-based learning approach to extract disease-manifesta-
tion phenotypic relationships from biomedical literature [32]. In
that study, we leveraged external knowledge of disease-manifesta-
tion from biomedical ontologies as prior knowledge to extract
many disease-manifestation pairs from MEDLINE. In this study,
we retarget the knowledge-driven pattern-learning approach to
accurately extract a large number of drug-SE pairs from MEDLINE.
Our study is based on the observation that researchers often
use certain predominant patterns to describe drug-SE-speciﬁc
associations. For example, in sentence ‘‘UGT1A128 genotype andirinotecan-induced neutropenia: dose matters’’ (PMID:
17728214), a typical pattern ‘‘DRUG-induced SE’’ is used. In this
study, we ﬁrst automatically learned drug-SE-speciﬁc patterns
using known drug-SE pairs derived from FDA drug labels. We then
used these learned patterns to extract many additional drug-SE
pairs from MEDLINE. Since our ultimate goal is to develop systems
approaches to exploit drug phenotype relationships for drug target
discovery, drug toxicity prediction, and drug repositioning,
accuracy and scalability of the algorithm are critical. Pattern-based
relationship extraction approaches have the advantage of being
both highly accurate and efﬁcient. Many pattern- or parsing-based
biomedical named entity recognition and relationship extraction
approaches have recently developed [7,9,15,33–35]. Our approach
is different from these approaches in that we leveraged upon a
large amount of prior knowledge in effectively ﬁnding patterns
with both high precisions and recalls and that we applied the
patterns to the whole MEDLINE in constructing a large-scale
drug-SE relationship knowledge base.2. Data and methods
The entire experimental process consists of the following steps:
(1) build a local MEDLINE search engine; (2) obtain known drug-SE
pairs as prior knowledge; (3) extract drug-SE pairs from MEDLINE;
(4) evaluate; and (5) analyze the correlation between drug side
effects and drug target genes, drug metabolism genes and drug
indications.2.1. Build a local MEDLINE search engine
We downloaded a total of 21,354,075 MEDLINE abstracts
(119,085,682 sentences) published between 1965 and 2011 from
the U.S. National Library of Medicine.1 Each sentence was syntacti-
cally parsed with the Stanford Parser [17] using the Amazon Cloud
computing service (a total of 3500 instance-hours with High-CPU
Extra Large Instance used). We used the publicly available informa-
tion retrieval library Lucene2 to create a local MEDLINE search engine
with indices created on both sentences and their corresponding parse
trees.2.2. Extract known drug-SE pairs as prior knowledge
We downloaded a total of 100,049 known drug-SE pairs from
SIDER (Side Effect Resource), a public, machine-readable side effect
resource that was automatically constructed from FDA package
inserts [18]. These pairs represented a total of 996 FDA-approved
drugs and 4199 adverse event terms.2.3. Build clean SE lexicons
An accurate and comprehensive SE lexicon is critical for the task
of drug-SE relationship extraction. We built a clean disease (or SE)
lexicon by combining and cleaning all disease terms in UMLS and
in Human Disease Ontology.3 This clean lexicon has been used on
our recent study of extracting disease-manifestation relationships
from MEDLINE [32]. We also created a SE lexicon based on the Med-
ical Dictionary for Regulatory Activities (MedDRA),4 which has been
used in one of our recent studies in building a cancer-drug-speciﬁc
side effect knowledge base [31].
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The drug lexicon was downloaded from DrugBank [25], and it
consisted of 6516 drugs, including both FDA-approved drugs and
experimental drugs. The decision of using drug names from Drug-
Bank instead of RxNORM or other sources was based on the fact
that DrugBank contains many experimental drugs in addition to
FDA-approved drugs.
2.5. Drug-SE relationship extraction
The knowledge-driven drug-SE relationship extraction system
is depicted in Fig. 1 and consists of: (1) Pattern Extraction, wherein
syntactical patterns associated with known drug-SE pairs are
extracted; (2) Pattern Ranking and Selection, wherein extracted pat-
terns are ranked and drug-SE-speciﬁc patterns are selected from
top ranked patterns; (3) Pair Extraction, wherein additional pairs
associated with selected patterns are extracted from MEDLINE;
and (4) Pair Ranking, wherein newly extracted drug-SE pairs are
ranked. The ranking scores of each pair was based on the ranking
scores of their associated patterns and its frequency in MEDLINE.
2.5.1. Pattern Extraction
In order to ﬁnd drug-SE-speciﬁc syntactic patterns, we used
known drug-SE pairs as search queries to the local search engine.
Sentences and their corresponding parse trees containing any
known drug-SE pairs were retrieved. The pattern ‘‘NP1 pattern
NP2’’, where the noun phrase pair NP1-NP2 is a known drug-SE
pair, was extracted from the retrieved parse trees. The pattern is
‘‘DRUG pattern SE’’ if a drug entity precedes a SE entity or ‘‘SE pat-
tern DRUG’’ if the opposite is true. For example, from the sentence
‘‘UGT1A128 genotype and irinotecan-induced neutropenia: dose
matters’’ (PMID: 17728214), we extracted the pattern ‘‘DRUG-
induced SE’’ between irinotecan and neutropenia. From the sen-
tence ‘‘Bradycardia induced by irinotecan: a case report’’ (PMID:
09861240), the pattern ‘‘SE induced by DRUG’’ was extracted. The
extra requirement that both the drug and SE terms must be noun
phrases in the retrieved sentences is to avoid extracting partial
or incorrect drug-SE pairs. For example, without the NP restriction,
partial drug-SE pair ‘‘acetazolamide-necrosis’’ will be extracted
from sentence ‘‘The high alkalinity of the injection vehicle of cer-
tain parenteral solutions of acetazolamide produces necrosis of
the skin upon sc injection’’ (PMID: 18809) since the input SE lexi-
con does not include the more complete SE term ‘necrosis of the
skin.’ By requiring that both drug and SE terms must be NP phrases,
no pair will be extracted from this sentence. In this way, high
precision is guaranteed.
2.5.2. Pattern Ranking and Selection
Not all patterns associated with known drug-SE pairs are neces-
sarily speciﬁc in describing drug-SE semantic relationships. In orderFig. 1. The drug-SE relationsto ﬁnd patterns that are associated with many known drug-SE pairs
(high recall) and are also speciﬁc in describing drug-SE relation-
ships (high precision), we ﬁrst ranked extracted patterns by the
number of their associated known drug-SE pairs. The ranking
scheme ranked patterns highly that were associated with many
known pairs (high recalls). However, not all patterns with high
recalls were drug-SE-speciﬁc patterns. For example, non-speciﬁc
patterns such as ‘‘DRUG and SE’’ can be associated withmany known
drug-SE pairs as well as non-drug-SE pairs. From the top-ranked
patterns, we manually selected drug-SE-speciﬁc syntactic patterns
such as ‘‘DRUG-induced SE’’ and ‘‘DRUG SE’’. The pattern ranking
and manual selection processes ensured the high recall
(top-ranked) and high precision (manually-selected) of selected
patterns. Because the pattern ranking algorithm effectively ranked
highly many drug-SE-speciﬁc patterns with both high precisions
and recalls, the manual selection process entailed minimal human
time to scan top-ranked patterns (less than 15 min).
2.5.3. Pair Extraction
The selected drug-SE-speciﬁc syntactic patterns were used as
search queries to the local MEDLINE search engine. Both sentences
and parse trees that contained these patterns were retrieved. We
extracted drug-SE pairs from the returned parse trees using the
pattern format‘‘NP1 pattern NP2,’’ wherein NP1 and NP2 were both
noun phrases, and the pattern was one of the selected patterns. In
addition, NP1 and NP2 were drug or SE terms from the input lexi-
cons. Drug-SE pairs that appeared in MEDLINE but not in SIDER
were determined additional drug-SE pairs that were discovered
by the algorithm.
2.5.4. Pair Ranking
We ranked the extracted drug-SE pairs based on their associ-
ated pattern scores and on their co-occurrence frequencies. A reli-
able drug-SE pair is assumed to be associated with reliable patterns
many times. The ranking score of a pair RSðRÞ is deﬁned as
following:
RSðRÞ ¼
Xn
i¼0
logðRSðPiÞÞ  countðPi;RÞ ð1Þ
RSðPiÞ is the score of its associated patterns (Pi) and is deﬁned as the
number of known drug-SE pairs from FDA drug labels that are asso-
ciated with the pattern. The count(Pi,R) is the number of times that
the pair is associated with the pattern in the entire MEDLINE
corpus.
2.6. Evaluation
The main goal of this study is to extract additional pairs from
MEDLINE that have not been captured in FDA drug labels. In order
to evaluate a MEDLINE-based drug-SE relationship extraction
algorithm, wemanually created three MEDLINE-speciﬁc evaluationhip extraction approach.
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effects that have been reported in MEDLINE. The other two sets
consist of drug-SE pairs reported in MEDLINE for ‘‘neutropenia’’
or ‘‘thrombocytopenia,’’ respectively. Irinotecan is a commonly
used chemotherapy drug. Both neutropenia and thrombocytopenia
are two hematologic side effects that are commonly associated
with chemotherapy drugs and many other drugs. To create an eval-
uation set of irinotecan-SE pairs, we ﬁrst retrieved a total of 10,044
sentences containing the term ‘‘irinotecan.’’ Three curators manu-
ally extracted side effects in which irinotecan was implicated from
the retrieved sentences. Note that curators did not use any SE lex-
icons. Only the pairs agreed upon by all three curators were used.
The resultant evaluation set consisted of 126 irinotecan-SE pairs.
Similarly, we created an evaluation dataset of 236 drug-neutrope-
nia pairs from 4040 MEDLINE sentences that contain ‘neutropenia’
and an evaluation dataset of 319 drug-thrombocytopenia pairs
from 16,618 sentences that contain ‘thrombocytopenia.’ The three
evaluation datasets were created independent of the method we
developed and the evaluators were not aware of the patterns we
used. However, due to the intensive manual curation effort
required (more than 40 h for each of the three curators), we only
created three evaluation datasets (one drug, two SEs), which may
not be representative of other drugs or SEs.
We used the learned patterns to extract drug-SE pairs from the
same set of sentences that contain irinotecan, neutropenia, and
thrombocytopenia. We evaluated the precision, recall, and F1 using
the manually created evaluation datasets. Precision is the number
of correct pairs divided by the number of all returned pairs and
recall is the number of correct pairs divided by the number of pairs
that should have been returned. The F1 score is a weighted average
of the precision and recall and is deﬁned as:
F1 ¼ 2  precision  recall
precisionþ recall : ð2Þ2.7. Comparison to the support vector machine (SVM), a supervised
machine learning approach
Support vector machines are supervised machine learning mod-
els [6] and are commonly used for biomedical relationship extrac-
tion tasks, including drug-SE relationship extraction [10]. The
SVM-based approach is comprised of two steps: sentence classiﬁ-
cation and drug-SE relationship extraction. We ﬁrst classiﬁed
MEDLINE sentences into drug-SE-related and not related. For
example, the sentence classiﬁer’s goal was to differentiate the
SE-related sentence ‘‘Associations between UGT1A16 or UGT1A16/
28 polymorphisms and irinotecan-induced neutropenia in Asian can-
cer patients’’ from the non-SE-related sentence ‘‘Prospective study of
paclitaxel and irinotecan for elderly patients with unresectable non-
small cell lung cancer.’’ We then extracted drug-SE co-occurrence
pairs from positively classiﬁed sentences. For sentence classiﬁca-
tion, we trained a two-class SVM-based sentence classiﬁer using
implementation in WeKa [11]. The SVM-based sentence classiﬁer
used polynomial kernel, bag-of-words feature, TF-IDF weighting,
stemming and stopwords-removal. The bag-of-words feature was
used since it is often the case that the appearance of one speciﬁc
word such as ‘toxicity’ can be used to determine whether a sen-
tence is drug-SE-related. The positive training data for the sentence
classiﬁer consisted of a total of 350,375 sentences, each of which
contained at least one known drug-SE pairs from SIDER. The nega-
tive training data comprised of equal number of sentences that
were randomly selected from the rest of MEDLINE sentences with
the assumption that the majority of MEDLINE articles were not
related to drug side effect reporting. The 10-fold cross validation
was used in training the sentence classiﬁer. We then used thetrained SVM sentence classiﬁer to classify sentences that were
used in the evaluation, namely the sentences containing the term
‘irinotecan’ and at least one SE, sentences containing the term
‘neutropenia’ and at least one drug, and sentences containing the
term ‘thrombocytopenia’ and at least one drug. The accuracy of
the sentence classiﬁer in classifying these sentence into SE-related
and -unrelated is 0.846 based on manual evaluation of 1000 ran-
domly selected sentences. We extracted drug-SE co-occurrence
pairs from positively classiﬁed sentences and compared to pairs
extracted from unclassiﬁed sentences. Precisions, recalls and F1
scores were used to evaluate the performance of drug-SE relation-
ship extractions and were compared among three methods:
pattern-based approach, SVM (classiﬁed sentences) and co-
occurrence (unclassiﬁed sentences). One tailed Z statistics was
used to test signiﬁcance.
2.8. Analyze the correlation between drug side effects and drug targets,
metabolism and indications
2.8.1. Correlation with drug target genes
We extracted a total of 10,478 drug-gene pairs from DrugBank
[25], representing 3454 drugs and 1816 genes. For drug-drug pairs
that share SEs at different cutoffs, we calculated the average
number of shared gene targets.
2.8.2. Correlation with drug metabolizing genes
Similar to the correlation analysis above, we analyzed shared
metabolism mechanism underlying drug-drug pairs with overlap-
ping SEs. We obtained from PharmGKB [24] a total of 4399 drug-
gene pairs with subtypes of pharmacokinetics (PK) or pharmacody-
namics (PD), representing 637 drugs and 859 genes. For drug-drug
pairs that share SEs at different cutoffs, we calculated the corre-
sponding average number of shared metabolism genes.
2.8.3. Correlation with drug indications
We extracted a total of 52,000 drug-disease pairs from Clinical-
Trials.gov (http://www.clinicaltrials.gov/), a registry of federally
and privately supported clinical trials conducted in the United
States and around the world (www.clinicaltrials.gov). The drug-
disease pairs contain 2035 drugs and 9591 diseases. For drug-drug
pairs that share SEs at different cutoffs, we calculated the
corresponding average number of shared disease indications.
2.8.4. Case studies of drug-drug relationships based on shared SEs and
shared drug indications
We selected two drugs, ﬂuorouracil and lovastatin, to examine
drug-drug relationships based on shared SEs and shared drug indi-
cations. We ﬁrst found all the drugs that shared any side effects
with them based on the drug-SE pairs extracted from MEDLINE
and drugs that shared any disease indications with them based
on the drug-disease pairs from ClinicalTrials.gov. We then ranked
the similar drugs based on Jaccard similarity coefﬁcient. The
Jaccard coefﬁcient measures similarity between two drugs, and is
deﬁned as the size of the intersection divided by the size of the
union of two drugs’ side effects or disease indications.
JðA;BÞ ¼ jA \ BjjA [ Bj : ð3Þ3. Results
3.1. Patterns associated with known drug-SE pairs
Using known drug-SE pairs from the SIDER database, we
extracted a total of 113,036 patterns in the format of ‘‘DRUG pattern
Fig. 2. Number of additional drug-SE pairs extracted from MEDLINE for each
selected pattern (‘‘DRUG pattern SE’’).
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these extracted patterns were associated with only one known
drug-SE pair, but one pair can be associated with multiple patterns.
We ranked the patterns based on the number of their associated
known drug-SE pairs. The top 10 ranked patterns along with the
numbers of associated known drug-SE pairs are listed in Table 1.
As shown in the table, many of the top-ranked patterns are indeed
typical drug-SE-speciﬁc patterns. In addition, these patterns are
representative and associated with many known drug-SE pairs
(since they were ranked based on the number of their associated
known drug-SE pairs). For instance, the top pattern ‘‘DRUG-induced
SE’’ was associated with 1743 known drug-SE pairs. Other top-
ranked drug-SE-speciﬁc patterns included ‘‘DRUG-associated with
SE,’’ ‘‘DRUG induces SE,’’ ‘‘SE associated with DRUG,’’ ‘‘SE due to
DRUG,’’ and ‘‘SE produced by DRUG,’’ among others.
Even though the patterns were extracted using known drug-SE
pairs, many top patternswere not speciﬁc for drug-SE relationships,
such as ‘‘DRUG and SE,’’ ‘‘DRUG in SE,’’ ‘‘SE with DRUG,’’ and ‘‘SE and
DRUG’’. In addition, some top patterns were in fact treatment-
speciﬁc, such as ‘‘DRUG for the treatment of DISEASE,’’ This may be
due to the fact that the SIDER dataset was constructed using text
mining approaches to extract drug-SE co-occurrence pairs from
the ‘‘Adverse Events’’ sections of FDA drug labels, which often
contain both drug-treatment (patient disease characteristics) and
drug-SE information. For accurate extraction of drug-SE pairs from
FDA drug labels, additional manual curation will be necessary.
3.2. Extraction of many additional drug-SE pair using selected
drug-SE-speciﬁc patterns
From top 100 ranked patterns, we manually selected 19 drug-
SE-speciﬁc patterns in the format of ‘‘DRUG pattern SE,’’ including
‘‘DRUG-induced SE,’’ ‘‘DRUG SE,’’ ‘‘DRUG-associated SE,’’ and
‘‘DRUG-related SE.’’ We also selected 35 patterns in the format of
‘‘SE pattern DRUG,’’ including ‘‘SE induced by DRUG,’’ ‘‘SE associated
with DRUG,’’ and ‘‘SE due to DRUG.’’ Using these selected patterns,
we extracted additional drug-SE pairs from MEDLINE sentences.
For instance, using the pattern ‘‘DRUG-induced SE,’’ we extracted
5684 distinct drug-SE pairs from MEDLINE. Amongst these pairs,
only 1743 pairs were included in SIDER, meaning that an addi-
tional 3941 pairs were discovered with this single pattern. For each
of these selected patterns, we extracted signiﬁcantly more pairs
from MEDLINE sentences compared to the ones captured in SIDER.
We extracted a total of 15,290 distinct drug-SE pairs from
MEDLINE sentences using the 19 selected patterns in the format
of ‘‘DRUG pattern SE,’’ representing a 504% increase from their asso-
ciated 2531 known drug-SE pairs in SIDER (Fig. 2). Similarly, we
extracted a total of 17,707 drug-SE pairs from MEDLINE sentences
using 35 selected patterns in the format of ‘‘SE pattern DRUG,’’ also
representing a 507% increase when compared to their associatedTable 1
Top ten frequent patterns and the numbers of associated known drug-SE pairs from
FDA drug labels. Drug side effect-speciﬁc patterns are highlighted.
DRUG pattern SE Pairs SE pattern DRUG Pairs
‘‘DRUG-induced SE’’ 1743 ‘‘SE with DRUG’’ 781
‘‘DRUG and SE’’ 545 ‘‘SE associated with DRUG’’ 786
‘‘DRUG SE’’ 523 ‘‘SE induced by DRUG’’ 645
‘‘DRUG induced SE’’ 390 ‘‘SE after DRUG’’ 450
‘‘DRUG-associated SE’’ 352 ‘‘SE due to DRUG’’ 427
‘‘DRUG in SE’’ 335 ‘‘SE, DRUG’’ 416
‘‘DRUG on SE’’ 325 ‘‘SE and SE’’ 409
‘‘Drug, SE’’ 220 ‘SE caused by DRUG’’ 340
‘‘DRUG for SE’’ 207 ‘‘SE during DRUG’’ 339
‘‘DRUG in the treatment
of SE’’
184 ‘‘SE following DRUG’’ 2962915 drug-SE pairs in SIDER (Fig. 3). In total, we extracted
38,817 drug-SE pairs from MEDLINE, the majority of which were
not captured in the SIDER database.
3.3. Precision, recall and F1 measures of extracted drug-SE pairs
We evaluated the precisions, recalls, and F1s of the extracted
drug-SE pairs using three manually created evaluation datasets:
Irinotecan-SE (126 pairs), Drug-Neutropenia (236 pairs), and Drug-
Thrombocytopenia (319 pairs). As shown in Table 2, using the
‘‘DRUG pattern SE’’ patterns (19 patterns), we extracted a total of
24 irinotecan-SE pairs, with a precision of 0.875 and a recall of
0.179. Using the ‘‘SE pattern DRUG’’ patterns (35 patterns), we
extracted a total of 35 irinotecan-SE pairs, representing a precision
of 0.686 and a recall of 0.205. By combining irinotecan-SE pairs
extracted using all selected patterns (54 patterns), we obtained a
total of 47 pairs, with a precision of 0.702, a recall of 0.282, and
an F1 of 0.402. For the other two evaluation datasets, we obtained
a precision of 0.855, a recall of 0.461, and an F1 of 0.599 for drug-
neutropenia pair extraction, and a precision of 0.943, a recall of
0.479, and an F1 of 0.635 for drug-thrombocytopenia pair extrac-
tion. In summary, the drug-SE pairs extracted using the selected
patterns had high precisions. However, the recalls were low com-
pared to precisions. In this study, we only used a handful of
selected patterns, which cannot possibly capture all the drug-SE
pairs in MEDLINE. In order to further increase the recall, we will
need to extract richer sets of patterns or complement our current
method with non-pattern-based approaches.
Even though we extracted many drug-SE pairs using the 54
selected drug-SE-speciﬁc patterns and the manually created clean
SE lexicons, the precisions were still not perfect and false positives
were introduced. For example, the drug-SE pair ‘‘warfarin-thrombo-
cytopenia’’ was erroneously extracted using one of the top patterns
(‘‘SE while on DRUG’’) from the sentence ‘‘One patient developed
epistaxis in the setting of thrombocytopenia while on warfarin
therapy.’’ (PMID: 20107495). In this sentence, thrombocytopenia
is an indication, not a side effect, of warfarin. In this case, depen-
dency tree analysis, manual curation, or an automatic method aug-
mented with prior knowledge (known drug-disease treatment
pairs) would be necessary in order to ensure extraction of valid
pairs or exclusion of erroneous ones.
3.4. The pattern-based approach has better precision and overall F1
but lower recall than the SVM and co-occurrence-based approaches
We compared the precisions, recalls and F1 scores of the
pattern-based, SVM and pure co-occurrence approaches using the
Fig. 3. Number of additional drug-SE pairs extracted from MEDLINE for each
selected pattern (‘‘SE pattern DRUG’’).
196 R. Xu, Q. Wang / Journal of Biomedical Informatics 51 (2014) 191–199irinotecan-SE evaluation dataset at ﬁve frequency cutoffs:P1 (126
pairs), P2 (63 pairs), P5 (30 pairs), P10 (15 pairs), and P20 (10
pairs). Comparison at different frequency cutoffs provided us a
more comprehensive picture how each method worked for both
rare and frequent pairs. The overall F1 scores of the pattern-based
approach were signiﬁcantly higher than those of either SVM or
pure co-occurrence-based approaches at all ﬁve cutoffs (Table 3).
For instance, at frequency cutoff of 5, the F1 score of the pattern-
based approach was 0.603, which is signiﬁcantly higher than
0.364 for SVM and than 0.355 for co-occurrence-based approach.
The recalls and F1 scores of the pattern-based approach increased
signiﬁcantly as the pair frequency increased, while the precisions
remained the same. Similar trends were observed for the otherTable 3
Comparison of the pattern-based, machine-learning and pure co-occurrence approaches at
and P20 (10 pairs).
Frequency cutoff Method
P1 Pattern-based
SVM
Cooc
P2 Pattern-based
SVM
Cooc
P5 Pattern-based
SVM
Cooc
P10 Pattern-based
SVM
Cooc
P20 Pattern-based
SVM
Cooc
Table 2
Precision, recall and F1 of the extracted drug-SE pairs. Test datasets: Irinotecan-SE (126 p
Goldstandard Pattern
Irinotecan-SE ‘‘DRUG pattern SE’’
‘‘SE pattern DRUG’’
Combined
Drug-neutropenia ‘‘DRUG pattern SE’’
‘‘SE pattern DRUG’’
Combined
Drug-thrombocytopenia ‘‘DRUG pattern SE’’
‘‘SE pattern DRUG’’
Combinedtwo evaluation datasets (drug-neutropenia and drug-thrombocy-
topenia) (data not shown). These results indicate that the pat-
tern-based approach is more effective in extracting frequent
drug-SE pairs than pairs that only appear in MEDLINE rarely.
3.5. Drug side effects positively correlate with both drug targeted
genes, drug metabolizing genes, and disease indications
To show the potential of this drug-SE association knowledge
base in drug target discovery and early drug toxicity prediction,
we analyzed the correlations between drug-SE pairs and drug-
associated gene targets and metabolizing genes. As shown in
Fig. 4, the number of shared gene targets increases as the number
of shared SEs increases (Pearson correlation coefﬁcient of 0.97). For
example, the average number of shared gene targets for all drug-
drug combinations is 0.332 (P0). The number increased to 0.565
for drug-drug pairs sharing one or more SEs and 2.824 for drug-
drug pairs with at least 30 overlapping SEs.
Drug metabolism genes are important factors in drug toxicity
prediction and personalized medicine (personalized drug efﬁcacy
and toxicity prediction). We examined the correlation between
drug metabolism genes and drug side effects. As shown in Fig. 5,
there is also strong positive correlation between shared drug side
effects and shared metabolism genes (Pearson correlation coefﬁ-
cient of 0.98). For example, the average number of shared metab-
olism genes for all drug-drug combinations is 0.521. The number
increased to 0.738 for drug-drug pairs sharing one or more SEs
and 2.665 for drug-drug pairs with at least 30 overlapping SEs.
To show the potential of this drug-SE association knowledge
base in drug repositioning, we also analyzed the correlations
between drug-SE pairs and drug indications. We observed strong
positive correlation between drug side effects and drug indicationsﬁve frequency cutoffs: P1 (126 pairs), P2 (63 pairs), P5 (30 pairs), P10 (15 pairs),
Precision Recall F1
0.702 0.282 0.402
0.251 0.967 0.398
0.238 0.989 0.383
0.702 0.384 0.496
0.271 0.873 0.414
0.262 0.889 0.404
0.702 0.528 0.603
0.235 0.800 0.363
0.225 0.833 0.355
0.702 0.765 0.732
0.231 1.000 0.375
0.208 1.000 0.345
0.702 0.833 0.762
0.179 0.700 0.286
0.167 0.800 0.276
airs), drug-neutropenia (236 pairs), and drug-thrombocytopenia (319 pairs).
Precision Recall F1
0.875 0.179 0.298
0.686 0.205 0.316
0.702 0.282 0.402
0.882 0.326 0.476
0.850 0.296 0.439
0.855 0.461 0.599
0.970 0.309 0.468
0.941 0.357 0.517
0.943 0.479 0.635
Fig. 6. Correlation between drug side effects (38,871 drug-SE pairs) and drug
indications (52,000 drug-disease pairs from ClinicalTrials.gov).
Fig. 4. Correlation between drug side effects (38,871 drug-SE pairs) and drug target
genes (10,478 drug-gene pairs from DrugBank).
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shared disease indications for all drug-drug combinations was
0.987. The number signiﬁcantly increased to 1.783 for pairs shar-
ing one or more SEs. As the number of shared SEs increased, the
number of shared disease indications increased signiﬁcantly
(Fig. 6). At cutoffP30, the average number of shared disease indi-
cations is 9.923. This strong correlation between drug side effects
and drug indications indicates that we can use this drug-SE
association dataset in drug repositioning tasks.
In summary, drug-drug pairs with overlapping side effects tend
to share both gene targets, metabolism genes and disease indica-
tions. Even though this positive correlations are expected, this
expected result demonstrates that we can use this dataset in
subsequent phenotype-driven drug target discovery, drug toxicity
prediction, and drug repositioning.
3.6. Examples of drug-drug relationships based on shared SEs and
shared disease indications
We selected two drugs, ﬂuorouracil which belongs to the family
of drugs called antimetabolites and is used in the treatment of
colorectal cancer and pancreatic cancer, and lovastatin which is a
member of the drug class of statins and used in combination withFig. 5. Correlation between side effects (38,871 drug-SE pairs) and drug metabo-
lism genes (4,399 drug-gene pairs from PharmGKB).diet, weight-loss, and exercise for lowering cholesterol and reduc-
ing risk of cardiovascular disease. Table 4 shows top 10 most sim-
ilar drugs for each given drug. For ﬂuorouracil, the majority of the
top ranked drugs based on both side effect proﬁle similarity and
indication proﬁle similarity are also cancer drugs, such as capecit-
abine and irinotecan. By examining the top-ranked drugs for lova-
statin based on side effect similarity, it is striking to see many of
them are statin drugs such as simvastatin (top 1), atorvastatin
(top 2) and rosuvastatin (top 4). The top ranked drugs based on dis-
ease indication similarity include not only statin drugs such as
pitavastatin but also other drugs used in the treatment of hyperlip-
idemia and cardiovascular diseases, such as colestipol (reducing
cholesterol) and dipyridamole (inhibiting thrombus formation).
This may be due to the fact that cardiovascular diseases are highly
complex diseases and many different types of drugs, including
statins, are used in the treatment, prevention and management
of this complex disease. Therefore, drugs that share indications
with lovastatin are not necessarily statins.4. Discussion
We have developed a pattern-based relationship extraction
method and accurately extracted a large number of drug-SE rela-
tionships from MEDLINE, the majority of which were not captured
in existing databases. Our approach signiﬁcantly outperformed the
state-of-art machine learning approach while entailing minimal
manual annotation. We also demonstrated that the extracted drug
side effects correlate positively with drug target genes, drug
metabolizing gens and drug indications.
Many aspects of the current method can be improved. First, this
pattern-based based method was limited to extracting drug-SE
pairs from sentences only. Though important pairs often appear
in sentences, some drug-SE pairs may only appear in abstracts. In
addition, many drug-SE pairs may only be described in full-text
articles, not in the title or abstract. Second, pattern-based relation-
ship extraction approaches in general have high precisions.
However, the recalls depend upon the size of the underlying text
corpus, the frequencies of the pairs in the corpus, and the usage
of the patterns in the text. The main goal of our study is to accu-
rately extract many additional drug-SE pairs from MEDLINE, so
we only selected a few speciﬁc patterns with high recalls to
guarantee both high precision and relatively high recall. Our
method will miss pairs that are not associated with these selected
patterns. Further improving the recall will require either manual
Table 4
Top 10 drugs drugs similar to ﬂuorouracil or to lovastatin.
Rank Fluorouracil Lovastatin
SE Similarity Indication Similarity SE Similarity Indication Similarity
1 Capecitabine Leucovorin Simvastatin Colestipol
2 Doxorubicin Oxaliplatin Atorvastatin Niacin
3 Carboplatin Cisplatin Bezaﬁbrate Dipyridamole
4 Paclitaxel Irinotecan Rosuvastatin Vitamin b6
5 Vinblastine Docetaxel Gemﬁbrozil Chlorthalidone
6 Docetaxel Cetuximab Levosimendan Pitavastatin
7 Irinotecan Capecitabine Genistein Pyridoxine
8 Metronidazole Bevacizumab Ajmaline Atenolol
9 Ergonovine Gemcitabine Flutamide Ezetimibe
10 Linezolid Pemetrexed Metformin Amlodipine
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non-pattern-based approaches. Third, we only performed primitive
correlation studies between drug side effects and drug-associated
target genes, metabolism gens and disease indications. The natural
next step of our study will be to investigate whether supplementa-
tion of drug-SE association datasets used in the two seminal stud-
ies of phenotype-driven network approaches for drug target
discovery [4] and drug toxicity prediction [3] with the drug-SE
pairs we extracted from biomedical literature will lead to different
network topologies with increased data completeness.
5. Conclusions
Computational approaches to systematically studying drug-SE
phenotype associations have great potential in drug target discov-
ery, drug repositioning, and drug toxicity prediction. However, the
bottleneck in such systems approaches is the lack of an accurate,
comprehensive, and machine-understandable knowledge base of
drug-SE associations. In this study, we presented a large-scale rela-
tionship extraction approach to accurately extract a large number
of drug-SE pairs fromMEDLINE. Our approach signiﬁcantly outper-
formed the state-of-art machine learning approach and achieved
an average precision of 0.833, a recall of 0.407, and an F1 of
0.545. We have shown that the drug-SE pairs extracted from
MELDINE correlate positively with drug target genes, drug metab-
olizing gens and drug indications. This unique drug-SE relationship
dataset that we created from the MEDLINE text corpus, when com-
bined with drug-SE associations from other sources and with other
‘omics’ data, can have profound implications in developing pheno-
type-driven network-based approaches to identifying new drug
targets, repositioning existing drugs for new diseases, and predict-
ing unexpected drug toxicities.
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